Dossier
clinicaltrials
trial early
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Key claim: A phase I trial is evaluating the optimal dose, safety, and efficacy of CPX-351 (liposomal daunorubicin-cytarabine) in patients with relapsed or refractory high-risk MDS or CMML.
Abstract
This phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or has not responded to treatment. Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Why this matters
Pending synthesis.